Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) — Increased michaelis constant (km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizers
- 1 November 1984
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 125 (1), 374-380
- https://doi.org/10.1016/s0006-291x(84)80378-2
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylationFEBS Letters, 1984
- OXIDATION POLYMORPHISM HAS CLINICAL RELEVANCEThe Lancet, 1984
- Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine‐type polymorphism of drug oxidationEuropean Journal of Clinical Investigation, 1984
- The genetic controlof bufuralol metabolisminmanEuropean Journal of Drug Metabolism and Pharmacokinetics, 1982
- Defective Oxidation of DrugsClinical Pharmacokinetics, 1982
- Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.British Journal of Clinical Pharmacology, 1981
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquineEuropean Journal of Clinical Pharmacology, 1980
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- The Carbon Monoxide-binding Pigment of Liver MicrosomesJournal of Biological Chemistry, 1964